Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05425355
Other study ID # 21-5733
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date November 4, 2022
Est. completion date June 1, 2024

Study information

Verified date October 2022
Source University Health Network, Toronto
Contact Nayeemur Rahman
Phone 416-603-5800
Email Nayeemur.Rahman@uhnresearch.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The INTACT-HIP trial study will evaluate feasibility of conducting a randomized, double-blinded controlled trial comparing postoperative treatment with intravenous (IV) acetaminophen versus oral acetaminophen, in older adults undergoing hip fracture surgery. The results of this feasibility trial will be used to inform designing a larger, multi-center, randomized controlled trial to assess the efficacy of IV acetaminophen compared to oral acetaminophen to reduce delirium and improve other clinical and patient-centered outcomes after hip fracture surgery. It will randomize 42 older adults to receive either oral or IV acetaminophen after hip fracture surgery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 42
Est. completion date June 1, 2024
Est. primary completion date March 1, 2024
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria: - 60 years of age and older - Patients who were ambulating without human assistance before fracture, with any type of non-neoplastic hip fracture - Patients undergoing surgical treatment as an inpatient Exclusion Criteria: - Patients with neoplastic hip fracture - Severe cognitive impairment (Montreal Cognitive Assessment (MoCA) <10) - Pre-existing delirium - Known hypersensitivity or allergy to acetaminophen - Severe or chronic liver or kidney dysfunction - Planned postoperative ventilation - Swallowing issues and/or dysphagia - English language limitation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Intravenous (IV) acetaminophen + oral placebo
Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group, the IV study drug will be IV acetaminophen and the oral study drug will be a placebo tablet.
Intravenous (IV) placebo plus oral acetaminophen
Postoperatively patients will receive both a tablet and an IV solution every 6 hours for 48 hours, for a total of 8 doses. In this group the IV study drug will be normal saline and the pill will be acetaminophen

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University Health Network, Toronto

References & Publications (3)

Chen DX, Yang L, Ding L, Li SY, Qi YN, Li Q. Perioperative outcomes in geriatric patients undergoing hip fracture surgery with different anesthesia techniques: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Dec;98(49):e18220. doi: 10.10 — View Citation

Harris MJ, Brovman EY, Urman RD. Clinical predictors of postoperative delirium, functional status, and mortality in geriatric patients undergoing non-elective surgery for hip fracture. J Clin Anesth. 2019 Dec;58:61-71. doi: 10.1016/j.jclinane.2019.05.010. — View Citation

Jahr JS, Breitmeyer JB, Pan C, Royal MA, Ang RY. Safety and efficacy of intravenous acetaminophen in the elderly after major orthopedic surgery: subset data analysis from 3, randomized, placebo-controlled trials. Am J Ther. 2012 Mar;19(2):66-75. doi: 10.1 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Trial feasibility-Recruitment Feasibility as assessed by recruitment rate. This will be assesses as proportion of patients enrolled in the study compared to the number of patients meeting the inclusion/exclusion criteria. 30 days
Primary Trial feasibility-Attrition Feasibility as assessed by attrition rates. This will be defined as the proportion of patients completing the study at follow-up compared to the enrolled patients. 30 days
Primary Trial feasibility-Availability of human resources Feasibility as assessed by lack of availability of human resources). Inability to include patient in study due to lack of pharmacist or research assistant availability will be documented. 30 days
Primary Trial feasibility-Comply study procedures Feasibility as assessed by failure to comply with study procedures. Failure to provide study drug at scheduled time will be documented. 30 days
Primary Trial safety Safety will be assessed as the number of participants experiencing intervention-related adverse or serious adverse events. 30 days
Secondary Postoperative pain Pain will be assessed using the visual analogue (VAS) scale (0-10) at rest and movement, with 0=no pain and 10=worst pain possible Before surgery, on day of surgery, and days 1,2,3 after surgery
Secondary Opioid consumption Oral morphine equivalents (OMEQS) in milligrams Before surgery, on day of surgery, and days 1,2,3 after surgery
Secondary Delirium Delirium incidence will be measured using the Confusion assessment method (CAM)-Long Form On day of surgery, and days 1,2, 3 after surgery
Secondary Cognitive dysfunction Cognitive dysfunction will be assessed using the Montreal Cognitive Assessment (MoCA) Before surgery and day 3 after surgery (or at discharge time if hospital stay less than 3 days after surgery)
Secondary Overall health and disability Overall health and disability will be measured using the WHO Disability Assessment Schedule, version 2.0 (WHODAS 2.0), a 12-item validated measure that assesses cognition, mobility, self-care, interpersonal relationships, work and household roles, and participation in society Baseline and at 30 days after surgery
Secondary Depression screen Patient Health Questionnaire (PHQ)-2 a 2-question questionnaire will be used as a validated measure to screen for depression. Before surgery and day 3 after surgery (or at discharge time if hospital stay less than 3 days after surgery)
Secondary Ambulation Ambulation will be assessed as the ability to walk 10 feet or across a room without human assistance Before surgery and day 3 after surgery (or at discharge time if hospital stay less than 3 days after surgery)
Secondary Post-operative adverse events Post-operative adverse events will be obtained from the study institution's National Surgical Quality Improvement Project (NSQIP) database as as death, ICU admission, standardized cardiac, respiratory and neurological postoperative events, and readmission to hospital. On day of surgery, days 1,2, 3 after surgery, and at 30 days after surgery
Secondary Discharge location Location of discharge after surgery At the time of discharge (at 1-3 days after surgery in most cases)
See also
  Status Clinical Trial Phase
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Enrolling by invitation NCT05534490 - Surgery and Functionality in Older Adults N/A
Recruiting NCT04792983 - Cognition and the Immunology of Postoperative Outcomes
Terminated NCT04612491 - Pre-operative Consultation on Patient Anxiety and First-time Mohs Micrographic Surgery
Recruiting NCT06397287 - PROM Project Urology
Recruiting NCT04444544 - Quality of Life and High-Risk Abdominal Cancer Surgery
Completed NCT04204785 - Noise in the OR at Induction: Patient and Anesthesiologists Perceptions N/A
Completed NCT03432429 - Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Recruiting NCT05370404 - Prescribing vs. Recommending Over-The-Counter (PROTECT) Analgesics for Patients With Postoperative Pain: N/A
Not yet recruiting NCT05467319 - Ferric Derisomaltose/Iron Isomaltoside and Outcomes in the Recovery of Gynecologic Oncology ERAS Phase 3
Recruiting NCT04602429 - Children's Acute Surgical Abdomen Programme
Completed NCT03124901 - Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor N/A
Completed NCT04595695 - The Effect of Clear Masks in Improving Patient Relationships N/A
Recruiting NCT06103136 - Maestro 1.0 Post-Market Registry
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04059328 - Novel Surgical Checklists for Gynecologic Laparoscopy in Haiti
Recruiting NCT03697278 - Monitoring Postoperative Patient-controlled Analgesia (PCA) N/A